(Total Views: 499)
Posted On: 09/28/2021 10:20:24 AM
Post# of 72440
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect a variety of organs and is predominantly seen in women. Treatment is focused on controlling symptoms and often involves the use of corticosteroids and other systemic immunosuppressant therapies [57, 58].
A recent study targeted increased PDE4 activity in lupus conditions using MRL/lpr mice (a mouse model developing severe lupus disease). Four groups of female MRL/lpr mice were injected at 5, 7, 9 and 13 weeks with one of ethanol, pentoxifylline, denbufylline, or NCS 613 (a novel PDE4 inhibitor). Results showed that both the survival time and the appearance of proteinuria of NCS 613-treated mice are significantly delayed, both with P values of 0.005 [59]. While study size was limited, the results demonstrate potential for the use of PDE4 inhibitors in patients with SLE.
MY GUESS and its only a guess,ok?... as to why Hydroxychloroquine works at high dose in outpatient Covid is again the antiPDE4 activity....keep in mind that Hydroxy is an anti parasitic but the antiPDE4 may be the active MOA w/ Covid...this appears to be a common denominator in my lit review...if the antiPDE4 activity of BRIL which is purely COMPLIMENTARY figuratively...lol...than to me this suggests a probable pos outcome in serious hospitalized patients particularly those initiated BRIL as early as possible on admission..the Compliment Cascade as Ive learned it by selling Gamimune-N early in my career at Bayer...is additive in its destruction as you progress through time all the way to EOD(end organ disease) and death....if this pans out w/ BRILs other qualities, including the new data on adenovirus...we are sitting on a GOLDMINE!
GLTA longs!
RP
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect a variety of organs and is predominantly seen in women. Treatment is focused on controlling symptoms and often involves the use of corticosteroids and other systemic immunosuppressant therapies [57, 58].
A recent study targeted increased PDE4 activity in lupus conditions using MRL/lpr mice (a mouse model developing severe lupus disease). Four groups of female MRL/lpr mice were injected at 5, 7, 9 and 13 weeks with one of ethanol, pentoxifylline, denbufylline, or NCS 613 (a novel PDE4 inhibitor). Results showed that both the survival time and the appearance of proteinuria of NCS 613-treated mice are significantly delayed, both with P values of 0.005 [59]. While study size was limited, the results demonstrate potential for the use of PDE4 inhibitors in patients with SLE.
MY GUESS and its only a guess,ok?... as to why Hydroxychloroquine works at high dose in outpatient Covid is again the antiPDE4 activity....keep in mind that Hydroxy is an anti parasitic but the antiPDE4 may be the active MOA w/ Covid...this appears to be a common denominator in my lit review...if the antiPDE4 activity of BRIL which is purely COMPLIMENTARY figuratively...lol...than to me this suggests a probable pos outcome in serious hospitalized patients particularly those initiated BRIL as early as possible on admission..the Compliment Cascade as Ive learned it by selling Gamimune-N early in my career at Bayer...is additive in its destruction as you progress through time all the way to EOD(end organ disease) and death....if this pans out w/ BRILs other qualities, including the new data on adenovirus...we are sitting on a GOLDMINE!
GLTA longs!
RP
(5)
(0)Scroll down for more posts ▼
